Key result
Bivalirudin demonstrates a lower incidence of bleeding risk compared to other anticoagulant drugs during PCI for ACS, despite an increased risk of stent thrombosis.
Why the study?
Does bivalirudin reduce thrombotic complications and bleeding risk in patients undergoing PCI for ACS?
Does bivalirudin reduce thrombotic complications and bleeding risk in patients undergoing PCI for ACS?
This review discusses the pharmacology and clinical evidence of bivalirudin in patients undergoing PCI for ACS, highlighting its lower bleeding risk but increased stent thrombosis risk.
Answers are grounded in this paper and cite their sources.
May favor bivalirudin in high-bleeding-risk ACS PCI; leaves open mitigation of stent thrombosis risk.
Acute coronary syndrome (ACS) represents the most common cause of death worldwide. Percutaneous coronary intervention (PCI) is the management of choice in patients with ACS and occurrence of intra-procedural thrombotic complications are an independent predictor of mortality and other major adverse cardiovascular events in patients undergoing PCI. According to current guideline, anticoagulation therapy is indicated during PCI in order to reduce the risk of thrombotic complications such as stent thrombosis. Among currently available anticoagulant drugs, bivalirudin demonstrates a lower incidence of bleeding risk, despite it is associated with an increased risk of stent thrombosis. The aim of this paper is to discuss the pharmacology of bivalirudin and the clinical evidences of its use in patients undergoing PCI for ACS.
No takes yet. Share an insight, caveat, or question.
Galasso et al. (2016) conducted a review in Acute coronary syndrome undergoing percutaneous coronary intervention. Bivalirudin vs. Other anticoagulant drugs was evaluated. Bivalirudin demonstrates a lower incidence of bleeding risk compared to other anticoagulant drugs during PCI for ACS, despite an increased risk of stent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: